Skip to main content
PsyBio Therapeutics Corp. logo

PsyBio Therapeutics Corp. — Investor Relations & Filings

Ticker · PSYBF ISIN · CA74464R1000 LEI · 549300KO32JSWBZIZP18 TSXV Manufacturing
Open in API
Filings indexed 249 across all filing types
Latest filing 2023-08-31 Regulatory Filings
Country CA Canada
Listing TSXV PSYBF

About PsyBio Therapeutics Corp.

www.psybiolife.com

PsyBio Therapeutics Corp. is an intellectual property-driven biotechnology company focused on the discovery, design, and development of psycho-targeted therapeutics for mental and neurological conditions, including CNS disorders. The company develops a portfolio of novel psychoactive compounds and their analogues. A key differentiator is its proprietary platform utilizing genetically modified bacteria for the scalable, biosynthetic manufacturing of psychoactive molecules, such as tryptamines. PsyBio is actively engaged in preclinical studies and developing its own compounds, aiming to improve treatments for various psychologic and neurologic conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that PsyBio Therapeutics has received government approval to manufacture biosynthetic tryptamines at scale. It discusses the company's progress, future clinical trials, and forward-looking statements. There is no financial data, regulatory filing, or detailed report content. The document is a corporate announcement about a milestone and regulatory approval, not a financial report, earnings release, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial compliance. It is best classified as a general regulatory announcement or corporate news release. Given the options, the closest fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or corporate announcements that do not fit other categories. The document length (9147 characters) and content confirm it is not a brief report publication announcement or a short notice but a full announcement. Confidence is high due to clear content and context.
2023-08-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CEO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2023. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer. The text does not contain the actual interim financial statements or substantive financial data but is a certification letter confirming the accuracy and completeness of those filings. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2981 characters), and it is clearly a certification, not the full interim report.
2023-08-31 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the CFO of PsyBio Therapeutics Corp. regarding the interim financial report and interim MD&A for the period ended June 30, 2023. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer. The text explicitly states it is a certification and does not contain the actual interim financial statements or substantive financial data, but rather attests to the accuracy and fair presentation of those filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (2990 characters), and it is clearly a certification letter, not the full interim report.
2023-08-31 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis of Financial Condition and Operating Performance' for the six months ended June 30, 2023 and 2022, dated August 31, 2023. It contains detailed discussion of financial condition, risks, forward-looking statements, and operational performance. The presence of a six-month period indicates it is an interim or quarterly report. The document references condensed consolidated interim financial statements prepared under IFRS, which supports classification as an Interim / Quarterly Report (IR). The length (15,000 characters) and content indicate it is the actual report, not just an announcement or certification. Therefore, the appropriate classification is IR with high confidence. H1 2023
2023-08-31 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document contains detailed financial statements including a condensed consolidated interim statement of financial position, statements of loss and comprehensive loss, and statements of changes in equity for the six months ended June 30, 2023 and 2022. The presence of unaudited interim financial data for a period shorter than a full fiscal year, along with comprehensive financial tables and notes, clearly indicates this is an interim or quarterly financial report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-08-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2023-05-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.